On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Penguin Solutions, Inc. (NASDAQ:PENG) “sells at a low multiple, and I don’t mind a low-multiple tech stock because they tend not to get hurt as much as the others.”
On the earnings front, Penguin Solutions reported better-than-expected fourth-quarter results on Oct. 6 and issued FY27 EPS guidance above estimates.
Penguin Solutions reported $566.69 million in fourth-quarter revenue, beating analyst estimates of $516.12 million, according to Benzinga Pro. Total revenue rose 68% year over year. The AI factory platform company posted fourth-quarter adjusted earnings of $1 per share, beating estimates of 78 cents per share.
When asked about Revolution Medicines, Inc. (NASDAQ:RVMD), he said, “I think you have to let it run.”
On Oct. 20, Revolution Medicines announced that it has begun treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer. The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation.
Price Action
- Penguin Solutions shares jumped 7.4% to settle at $58.99 on Tuesday.
- Revolution Medicines shares rose 1.3% to close at $186.22 during the session.
See More:
Top Value Stocks
Photo via Shutterstock
Recent Comments